A recent mixed securities shelf registration filing by Thermo Fisher Scientific has prompted speculation from industry insiders and investors, with prominent advisors predicting further acquisitions for the company throughout 2016
For our latest Data Visualisation project, the Evolution Global Team analysed historical new drug approval statistics and the current clinical trials pipeline to identify trends that highlight the rise and
China made its boldest overseas takeover move yet this week, announcing that state-owned company ChemChina has submitted a $43 billion bid for Swiss seeds and pesticides group Syngenta with the
The UK’s Human Fertilisation and Embryology Authority (HFEA) has given the go-ahead for a select group of Francis Crick Institute researchers to edit the genomes of human embryos. The group,
Advanced Cell Diagnostics and Leica Biosystems have announced a comprehensive partnership to develop and commercialise tissue-based diagnostic tests based on ACD’s RNAscope in situ hybridisation (ISH) assays and Leica’s clinical
Thermo Fisher Scientific (NYSE:TMO) have announced an agreement to acquire Affymetrix (NASDAQ:AFFX) for approximately $1.3 billion, or $14.00 per share, in cash. The acquisition was unanimously approved by the boards
In recent years Next Generation Sequencing instrumentation has become much more accurate, efficient and affordable, enabling researchers to collect, sequence and analyse genomes with increasing ease. Consequently researchers are developing
Last month researchers at Washington University in St. Louis announced the ongoing development of ViroCap, a novel test capable of detecting nearly all viruses known to infect humans and animals.
Earlier this month Thermo Fisher Scientific announced the launch of two novel next-generation sequencing (NGS) instruments, the Ion S5 and the Ion S5 XL benchtop systems, which combine the ability
On August 31, 2015 Google Life Sciences and French pharma giant Sanofi announced that the two companies will work together on new digital technology and tools for the treatment of
Evolution Global Talent Attraction recently signed a contract to provide human capital to newly formed company QuantiHealth in China. QuantiHealth was founded by Zhao Bowen, who was named as one
Evolution’s 2015 Biopharmaceutical IPO Analysis was featured in a recent article on Forbes. Science & Business correspondent Arlene Weintraub’s article, titled “Will Wall Street Volatility Dampen The Sizzling Biotech IPO
In the first half of 2015 fifty therapeutics companies finalised their IPOs, raising over $5.17 billion across multiple global exchanges. Evolution Global Talent Attraction analysed the therapeutic targets and IPO
Evolution Global Talent Attraction’s latest market research report looks at the capacity and content of biopharmaceutical production in Europe, the Middle East and Africa. Rather than publish a lengthy report,
NantKwest, Inc. (formerly known as Conkwest, Inc.), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer,
